Answers are grounded in this paper and cite their sources.
Rearranged during transfection (RET)‑activated gliomas are exceptionally rare and associated with a poor prognosis, and there are no established effective therapies. Clinical data on RET inhibitors are predominantly derived from solid tumors such as non‑small cell lung cancer and medullary thyroid carcinoma, with data for central nervous system tumors being scarce. The present report describes a case of pleomorphic xanthoastrocytoma with RET activation that progressed following the Stupp regimen but subsequently exhibited a favorable response to pralsetinib, teniposide and bevacizumab. The tumor area decreased from 4.84 cm2 before treatment to 1.92 cm2 (calculated based on the longest and maximum perpendicular diameters).
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: